Cannabis has been increasing its footprint in veterinary medicine—showing up in everything from accidental pet exposures to intentional use of cannabidiol (CBD)-based products in clinical care. At the same time, the regulatory environment has been changing, and studies of the safety and effectiveness of CBD in animals have been growing.
A newly updated report, Cannabis in Veterinary Medicine, will help you stay informed and ready as research and regulations continue to evolve. Find it with other resources related to cannabis use in pets at avma.org/Cannabis.
What’s inside the report?
Whether you’re new to the report or a regular reader, the update has valuable insights for every reader. Foundational content from the previous edition remains. For example:
- Relevant history of cannabis in the U.S.
- Deep dive into cannabis pharmacology and the endocannabinoid system
- Overview of analytic testing and quality control in the cannabis industry
What’s new? The updated edition captures the latest clinical developments and legal considerations. These include:
- Safety data and pharmacokinetics of CBD in dogs and cats
- Clinical trials exploring CBD-rich hemp products in dogs, cats, and horses
- Regulatory updates at both the federal and state levels
The landscape has changed substantially since the previous edition of the report—especially related to the number and scope of published clinical trials. You’ll find expanded insights into therapeutic potential of CBD for pain management, neurologic and behavioral disease, atopic dermatitis, and stress amelioration in animals.
Why it matters
From considering cannabinoid therapies to answering client questions about CBD, this updated report will equip you with the evidence-based context you need for your client conversations and clinical decisions.
aph-cannabis-resources-report-v4-2025
